Cocrystal Pharma, Inc.COCP
Price (close)
$1.17
Market cap
$16.1M
P/E
—
Revenue (TTM)
—
Net income
-$9.9M
Dividend yield
—
1-year total return
-6.4%
Net margin
—
Revenue growth
—
Debt / equity
—
What Cocrystal Pharma, Inc. does.
novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and
Nobel Prize winning expertise with the goal of creating viable antiviral drugs. These technologies are designed to efficiently deliver
small molecule therapeutics that are safe, effective, and convenient to administer. We have identified promising discovery, preclinical
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.0M | — | — | — | — | — |
| Net income | -$9.6M | -$14.2M | -$38.8M | -$18.0M | -$17.5M | -$8.8M |
| Free cash flow | -$10.1M | -$12.8M | -$21.5M | -$14.8M | -$16.5M | -$8.2M |
More on COCP.
- Cocrystal Pharma, Inc. summary
- Cocrystal Pharma, Inc. financial statements
- Cocrystal Pharma, Inc. key metrics
- Cocrystal Pharma, Inc. health scores and style box
- Cocrystal Pharma, Inc. earnings
- Cocrystal Pharma, Inc. dividends
- Cocrystal Pharma, Inc. valuation
- Cocrystal Pharma, Inc. ownership and insiders
- Cocrystal Pharma, Inc. peers
Figures from Cocrystal Pharma, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.